DexCom Inc annual ebitda for fiscal TTM was $1.5 billion, an increase of 8.7% from $1.4 billion in fiscal 2025. All figures are reported results from public filings — no estimates or projections.
| EBITDA (annual) | TTM → 2026-03-31 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EBITDA | $1.5B | $1.4B | $946M | $917M | $565M | $378M | $377M | $213M | ($75M) | ($20M) | ($49M) | ($46M) | ($13M) | ($22M) | ($49M) | ($41M) | ($51M) | ($43M) | ($50M) | ($43M) | ($47M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| EBITDA (quarterly) | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|
| EBITDA | $337M | $410M | $421M | $309M | $219M | $274M | $237M | $245M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
More DXCM metrics: Revenue · Gross Profit · Operating Income · Net Income · EPS · Free Cash Flow · Shares Outstanding
All DXCM financial statements → Interactive DXCM charts →
About TickerBase · Data methodology & sources